{"entity":{"id":"avaglio","kind":"trial","name":"AVAglio","aka":[],"tldr":"AVAglio tested adding the anti-blood-vessel drug bevacizumab to standard radiotherapy and chemotherapy for newly diagnosed glioblastoma; the tumours took longer to grow on scans, but people did not live any longer, so bevacizumab is not used up front for this cancer.","summary":"AVAglio was a double-blind placebo-controlled phase 3 trial in newly diagnosed glioblastoma. After surgery or biopsy, patients received radiotherapy with concurrent and adjuvant temozolomide and were randomised to bevacizumab or placebo throughout, followed by single-agent maintenance.\n\nBevacizumab prolonged progression-free survival, one of the two primary endpoints, but did not improve overall survival, the other. The parallel US trial RTOG 0825 reached the same conclusion, and together they closed the question of first-line bevacizumab in glioblastoma; the drug remains in use for symptomatic relief and at recurrence, where its 2009 accelerated approval was granted.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT00943826","url":"https://clinicaltrials.gov/study/NCT00943826"}],"tags":["subtype-trials"],"related":[],"cancers":["glioblastoma","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab-glioma","temozolomide"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["olivier-chinot"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00943826","phase":"3","setting":"Newly diagnosed glioblastoma: bevacizumab or placebo added to radiotherapy with temozolomide and continued as maintenance","sponsor":"Roche","result":"Bevacizumab added to radiotherapy and temozolomide prolonged progression-free survival but not overall survival in newly diagnosed glioblastoma.","yearReported":2014,"enrolled":921,"outcomes":[{"endpoint":"Progression-free survival (investigator-assessed)","primary":true,"unit":"months","arms":[{"name":"Bevacizumab + radiotherapy-temozolomide","n":458,"value":10.6},{"name":"Placebo + radiotherapy-temozolomide","n":463,"value":6.2}],"hr":0.64,"ci":[0.55,0.74],"p":"<0.001","source":"https://doi.org/10.1056/nejmoa1308345"},{"endpoint":"Overall survival","primary":true,"arms":[{"name":"Bevacizumab + radiotherapy-temozolomide","n":458,"note":"Medians not reported in the abstract"},{"name":"Placebo + radiotherapy-temozolomide","n":463}],"hr":0.88,"ci":[0.76,1.02],"p":"0.10","source":"https://doi.org/10.1056/nejmoa1308345"},{"endpoint":"Overall survival at 2 years","unit":"%","arms":[{"name":"Bevacizumab + radiotherapy-temozolomide","n":458,"value":33.9},{"name":"Placebo + radiotherapy-temozolomide","n":463,"value":30.1}],"p":"0.24","source":"https://doi.org/10.1056/nejmoa1308345"},{"endpoint":"Grade 3 or higher adverse events","unit":"%","arms":[{"name":"Bevacizumab + radiotherapy-temozolomide","value":66.8},{"name":"Placebo + radiotherapy-temozolomide","value":51.3}],"source":"https://doi.org/10.1056/nejmoa1308345"}]},"route":"/trials/avaglio/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"person":[{"id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/"}]}}